LMTX (hydromethylthionine) / TauRx 
Welcome,         Profile    Billing    Logout  

2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LMTX (hydromethylthionine) / TauRx
LUCIDITY, NCT03446001 / 2017-003558-17: Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment

Completed
3
598
Europe, Canada, US
TRx0237 16 mg/day, Placebo, TRx0237 8 mg/day
TauRx Therapeutics Ltd
Alzheimer Disease
03/22
04/23
NCT03539380: TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease

Available
N/A
NA
TRx0237
TauRx Therapeutics Ltd
Alzheimer Disease
 
 

Download Options